In 1977, Crawhall, Thoene and Schneider discovered that the pathologic accumulation of cystine in cells from cystinosis patients could be reversed by cysteamine treatment—thereby bypassing the mutant lysosomal cystine transporter, known as Cystinosin, encoded by the CTNS gene (1). The gene discussed is CTNS; the disease is cystinosis.